Fidelity Investments
FHTX icon

Fidelity Investments’s Foghorn Therapeutics FHTX Stock Holding History

Fidelity Investments’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.9M Buy
6,047,198
+650,384
+12% +$3.57M ﹤0.01% 1637
2025
Q4 		$29.1M Sell
5,396,814
-77,677
-1% -$352K ﹤0.01% 1642
2025
Q3 		$26.8M Sell
5,474,491
-60,025
-1% -$318K ﹤0.01% 1656
2025
Q2 		$26M Sell
5,534,516
-54,358
-1% -$227K ﹤0.01% 1610
2025
Q1 		$20.4M Sell
5,588,874
-100,845
-2% -$460K ﹤0.01% 1671
2024
Q4 		$26.9M Sell
5,689,719
-644,265
-10% -$4.69M ﹤0.01% 1621
2024
Q3 		$59M Sell
6,333,984
-49,307
-0.8% -$357K ﹤0.01% 1307
2024
Q2 		$36.7M Buy
6,383,291
+3,692,155
+137% +$22M ﹤0.01% 1433
2024
Q1 		$18.1M Sell
2,691,136
-118,873
-4% -$660K ﹤0.01% 1695
2023
Q4 		$18.1M Sell
2,810,009
-88,210
-3% -$381K ﹤0.01% 1665
2023
Q3 		$14.5M Sell
2,898,219
-9,506
-0.3% -$73.3K ﹤0.01% 1708
2023
Q2 		$20.5M Sell
2,907,725
-107,287
-4% -$750K ﹤0.01% 1625
2023
Q1 		$18.7M Sell
3,015,012
-102,382
-3% -$670K ﹤0.01% 1632
2022
Q4 		$19.9M Sell
3,117,394
-298,938
-9% -$2.25M ﹤0.01% 1615
2022
Q3 		$29.3M Sell
3,416,332
-17,546
-0.5% -$226K ﹤0.01% 1470
2022
Q2 		$46.7M Buy
3,433,878
+238,012
+7% +$3.07M ﹤0.01% 1296
2022
Q1 		$48.7M Buy
3,195,866
+711,032
+29% +$9.76M ﹤0.01% 1398
2021
Q4 		$56.8M Sell
2,484,834
-35,300
-1% -$507K ﹤0.01% 1374
2021
Q3 		$35.1M Sell
2,520,134
-20,300
-0.8% -$225K ﹤0.01% 1571
2021
Q2 		$27.1M Sell
2,540,434
-32,600
-1% -$355K ﹤0.01% 1709
2021
Q1 		$33.2M Sell
2,573,034
-7,600
-0.3% -$125K ﹤0.01% 1572
2020
Q4 		$50.1M Buy
+2,580,634
New +$49.4M ﹤0.01% 1324

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's FHTX Position: Q1 2026 in Review

Fidelity Investments increased its Foghorn Therapeutics (FHTX) stake by 12% in Q1 2026, buying an estimated $3.57M and bringing the position to 6,047,198 shares worth $28.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Fidelity Investments first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $59M in Q3 2024. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Fidelity Investments held 6,047,198 shares of Foghorn Therapeutics worth $28.9M as of Q1 2026.
  • Fidelity Investments bought 650,384 Foghorn Therapeutics shares in Q1 2026, an estimated $3.57M.
  • Foghorn Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1637 holding.
  • Fidelity Investments first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Fidelity Investments's Foghorn Therapeutics position peaked at $59M in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.